neurology

News in Brief: Atogepant decreases migraine days; Pregabalin warning after doctor shopping death; Rare Bell’s palsy risk after COVID-19 vax

Atogepant decreases monthly migraine days People with migraine who took atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist, had an average of three to four fewer migraines each month, according to findings from a phase 3, double-blind trial The multi centre clinical trial looked at three doses of the investigational drug -10 mg, ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic